Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.

MLA

Shaw, Christine A., et al. “Safety and Immunogenicity of an MRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.” Journal of Infectious Diseases, vol. 230, no. 3, Sept. 2024, pp. e647–56. EBSCOhost, https://doi.org/10.1093/infdis/jiae081.

APA

Shaw, C. A., Essink, B., Harper, C., Mithani, R., Kapoor, A., Dhar, R., Wilson, L., Guo, R., Panozzo, C. A., Wilson, E., Simorellis, A. K., Reuter, C., Stoszek, S. K., Chen, G. L., Das, R., & Goswami, J. (2024). Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults. Journal of Infectious Diseases, 230(3), e647–e656. https://doi.org/10.1093/infdis/jiae081

Chicago

Shaw, Christine A, Brandon Essink, Charles Harper, Runa Mithani, Archana Kapoor, Rakesh Dhar, Lauren Wilson, et al. 2024. “Safety and Immunogenicity of an MRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.” Journal of Infectious Diseases 230 (3): e647–56. doi:10.1093/infdis/jiae081.